Payment overview · 2025
General Payments
$145.54
6 reported records · 6 companies
Healthcare provider profile · identity verified
Philip Matthew Oconnell, MD
Allopathic & Osteopathic Physicians|Family Medicine · ST. MARYS, GA · NPI 1518930841
Verified facts
What the public records show
CMS Open Payments records show Philip Matthew Oconnell, MD received $145.54 in general payments during 2025 across 6 reported records.
Boston Scientific Corporation accounted for 26.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $38.00 | 26.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $24.32 | 16.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.92 | 15.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.30 | 14.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.79 | 14.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.21 | 13.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $145.54 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EMBOLD Fibered Normalized: embold fibered |
Device | Boston Scientific Corporation | $38.00 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 420 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 306 | 90 |
| Lisinopril | Lisinopril | 298 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 283 | 83 |
| Losartan Potassium | Losartan Potassium | 234 | 70 |
| Omeprazole | Omeprazole | 205 | 71 |
| Diclofenac Sodium | Diclofenac Sodium | 177 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 50 |
| Metformin Hcl | Metformin Hcl | 157 | 57 |
| Furosemide | Furosemide | 141 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 50 |
| Simvastatin | Simvastatin | 129 | 39 |
| Trazodone Hcl | Trazodone Hcl | 118 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 102 | 30 |
| Meloxicam | Meloxicam | 101 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 98 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 34 |
| Sertraline Hcl | Sertraline Hcl | 93 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 91 | 78 |
| Alprazolam | Alprazolam | 89 | 19 |
| Gabapentin | Gabapentin | 88 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 13 |
| Ozempic | Semaglutide | 78 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 28 |
| Glipizide Er | Glipizide | 73 | 25 |
| Eliquis | Apixaban | 70 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 20 |
| Ibuprofen | Ibuprofen | 58 | 15 |
| Montelukast Sodium | Montelukast Sodium | 58 | 16 |
| Prednisone | Prednisone | 58 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 14 |
| Famotidine | Famotidine | 52 | 19 |
| Buspirone Hcl | Buspirone Hcl | 49 | 17 |
| Carvedilol | Carvedilol | 49 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 41 |
| Lovastatin | Lovastatin | 49 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 17 |
| Potassium Chloride | Potassium Chloride | 42 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Clonazepam | Clonazepam | 40 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 12 |
| Allopurinol | Allopurinol | 39 | 12 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Naproxen | Naproxen | 37 | suppressed |
| Jardiance | Empagliflozin | 36 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 11 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Azithromycin | Azithromycin | 34 | 33 |
| Ibandronate Sodium | Ibandronate Sodium | 34 | 15 |
| Novolog Flexpen | Insulin Aspart | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 21 |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Spironolactone | Spironolactone | 26 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 16 |
| Finasteride | Finasteride | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 12 |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $145.54 · 6 records | Boston Scientific Corporation | ABRYSVO, COMIRNATY, EMBOLD Fibered, Kerendia, LEQVIO, PREVNAR 20, QULIPTA, TZIELD, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error